Improving Outcomes for Patients With Moderate to Severe Psoriasis

Use this Interactive Decision Support Tool to compare your treatment choices for specific patient situations with those of 5 experts. Then, view an on-demand Interactive Virtual Presentation with complementary downloadable slides to reinforce optimal patient management strategies for moderate to severe psoriasis.
M Alan Menter, MD

Interactive Virtual Presentation

In this CME-certified interactive presentation, M. Alan Menter, MD, discusses strategies to optimize disease response, symptom improvement, and comorbidity management for patients with moderate to severe psoriasis based on recent guidelines and available clinical data.

M Alan Menter, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: October 14, 2016 Expired: No longer available for credit

In this downloadable slideset, M. Alan Menter, MD, reviews strategies for formulating optimal psoriasis treatment plans, with particular focus on evaluating the long-term safety of biologics, managing comorbidities such as cardiovascular risk and depression, and incorporating patient-reported outcomes and validated disease severity assessment tools.

Released: October 14, 2016

Interactive Decision Support Tool

Use this online tool to compare your management selections for your patients with moderate to severe psoriasis with expert recommendations from Joel M. Gelfand, MD, MSCE; Robert E. Kalb, MD; Neil J. Korman, MD, PhD; M. Alan Menter, MD; and Abby S. Van Voorhees, MD.

Released: June 15, 2016
Jointly provided by Boston University School of Medicine and Clinical Care Options, LLC.

Boston University School of Medicine
Continuing Medical Education
72 East Concord Street, A402
Boston, Massachusetts 02118

(617) 638-4605
(617) 638-4905 (Fax)
http://www.bu.edu/cme

Supported by educational grants from
Lilly USA, LLC
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue